The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Ace revisited: A new target for structure-based drug design
Open accessAbstract
Current-generation angiotensin-converting enzyme (ACE) inhibitors are widely used for cardiovascular diseases, including high blood pressure, heart failure, heart attack and kidney failure, and have combined annual sales in excess of US $6 billion. However, the use of these ACE inhibitors, which were developed in the late 1970s and early 1980s, is hampered by common side effects. Moreover, we now know that ACE actually consists of two parts (called the N- and C-domains) that have different functions. Therefore, the design of specific domain-selective ACE inhibitors is expected to produce next-generation drugs that might be safer and more effective. Here we discuss the structural features of current inhibitors and outline how next-generation ACE inhibitors could be designed by using the three-dimensional molecular structure of human testis ACE. The ACE structure provides a unique opportunity for rational drug design, based on a combination of in silico modelling using existing inhibitors as scaffolds and iterative lead optimization to drive the synthetic chemistry.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rigat, B., Hubert, C., Alhenc-Gelas, F., Cambien, F., Corvol, P., & Soubrier, F. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114844 · Cited by 3,767
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung
Cushman, D. W., & Cheung, H. S. (1971) · Biochemical Pharmacology · doi:10.1016/0006-2952(71)90292-9 · Cited by 2,625
Handbook of Proteolytic Enzymes
(2004) · Elsevier eBooks · doi:10.1016/c2009-0-03628-9 · Cited by 2,616
STUDIES ON EXPERIMENTAL HYPERTENSION
Goldblatt, H., Lynch, J., Hanzal, R. F., & Summerville, W. W. (1934) · Journal of Experimental Medicine · doi:10.1084/jem.59.3.347 · Cited by 2,142
Pitt, B., Poole-Wilson, P. A., Segal, R., Martinez, F. A., Dickstein, K., Camm, A. J., Konstam, M. A., Riegger, G., Klinger, G. H., Neaton, J., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02213-3 · Cited by 1,961
Hypertension : pathophysiology, diagnosis, and management
Laragh, J. H., & Brenner, B. M. (1995) · Raven Press eBooks · Cited by 1,932
Ondetti, M. A., Rubin, B., & Cushman, D. W. (1977) · Science · doi:10.1126/science.191908 · Cited by 1,856
Zinc coordination, function, and structure of zinc enzymes and other proteins
Vallee, B. L., & Auld, D. S. (1990) · Biochemistry · doi:10.1021/bi00476a001 · Cited by 1,777
Wolf-Maier, K. (2003) · JAMA · doi:10.1001/jama.289.18.2363 · Cited by 1,737
Cited by
Artificial intelligence in drug development: Present status and future prospects
Mak, K.-K., & Pichika, M. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.014 · Cited by 1,018
ACE2: from vasopeptidase to SARS virus receptor
Turner, A. J., Hiscox, J. A., & Hooper, N. M. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.04.001 · Cited by 517
Krumsiek, J., Suhre, K., Evans, A. M., Mitchell, M. W., Mohney, R. P., Milburn, M. V., Wägele, B., Römisch-Margl, W., Illig, T., Adamski, J., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1003005 · Cited by 197
“Moreover, the ACE protein is a target for various pharmaceuticals (ACE inhibitors), especially in the treatment of hypertension [39].”
BackgroundJiménez-Moreno, N., Esparza, I., Bimbela, F., Gandía, L. M., & Ancín-Azpilicueta, C. (2020) · Critical Reviews in Environmental Science and Technology · doi:10.1080/10643389.2019.1694819 · Cited by 188
Metadata
- Authors
- Acharya, K. R., Sturrock, E. D., Riordan, J. F., & Ehlers, M. R. W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2003-11-01
- Volume
- 2
- Issue
- 11
- Pages
- 891-902
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1990840149
- Cited by
- 342
- References
- 91
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ace revisited: A new target for structure-based drug design. https://app.cochat.ai/papers/10.1038/nrd1227
- The paper
- Acharya, K. R., Sturrock, E. D., Riordan, J. F., & Ehlers, M. R. W. (2003). Ace revisited: A new target for structure-based drug design. Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd1227
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
